Jazz Pharmaceuticals posted on LinkedIn:
“Meet Nick, a stomach cancer advocate using his voice to raise awareness and support for others navigating similar diagnoses.
Reflecting on his journey with HER2+ gastroesophageal adenocarcinoma (GEA) – a complex, fast-growing type of cancer with an overexpression of the HER2 protein that can affect the stomach, gastroesophageal junction and esophagus – Nick credits his health today to having a care team who he could trust and rely on throughout his treatment.
He shares his story to help foster greater understanding of this form of cancer and highlight the importance of continued research into HER2+ cancers, where therapies that specifically target the HER2 protein are offering patients like Nick a chance for improved outcomes.
Hear his perspective.”
Other articles on Gastroesophageal Adenocarcinoma on OncoDaily.